Oura’s accelerating revenue trajectory and September 3 S-1 filing for a Nasdaq listing under ticker OURA underpin trader focus on closing market caps above $15 billion. The company reported $1.21 billion in revenue for the nine months ended June 30, 2026, up 74% year-over-year, alongside 5 million paid members and 89% gross margins on membership subscriptions. This growth from $908 million in fiscal 2025 supports a targeted raise of up to $3 billion at valuations exceeding the prior $11 billion Series E mark, with Goldman Sachs, Morgan Stanley, and JPMorgan leading the syndicate. Market-implied odds remain dispersed across the $15–20 billion range amid uncertainty over final pricing, share supply from selling shareholders, and broader IPO sentiment in the health-tech sector.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$20B+ 30%
$15B–$17.5B 26%
$17.5B–$20B 21%
$12.5B–$15B 19%
$444,715 Vol.
$444,715 Vol.
<$7.5B
<1%
$7.5B–$10B
<1%
$10B–$12.5B
3%
$12.5B–$15B
19%
$15B–$17.5B
26%
$17.5B–$20B
21%
$20B+
30%
No IPO before January 2027
<1%
$20B+ 30%
$15B–$17.5B 26%
$17.5B–$20B 21%
$12.5B–$15B 19%
$444,715 Vol.
$444,715 Vol.
<$7.5B
<1%
$7.5B–$10B
<1%
$10B–$12.5B
3%
$12.5B–$15B
19%
$15B–$17.5B
26%
$17.5B–$20B
21%
$20B+
30%
No IPO before January 2027
<1%
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Mercato aperto: May 26, 2026, 12:28 PM ET
Risolutore
0x69c47De9D...If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Risolutore
0x69c47De9D...Oura’s accelerating revenue trajectory and September 3 S-1 filing for a Nasdaq listing under ticker OURA underpin trader focus on closing market caps above $15 billion. The company reported $1.21 billion in revenue for the nine months ended June 30, 2026, up 74% year-over-year, alongside 5 million paid members and 89% gross margins on membership subscriptions. This growth from $908 million in fiscal 2025 supports a targeted raise of up to $3 billion at valuations exceeding the prior $11 billion Series E mark, with Goldman Sachs, Morgan Stanley, and JPMorgan leading the syndicate. Market-implied odds remain dispersed across the $15–20 billion range amid uncertainty over final pricing, share supply from selling shareholders, and broader IPO sentiment in the health-tech sector.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato


Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti